# Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

> **NCT01642251** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 156 (actual)

## Conditions studied

- Extensive Stage Small Cell Lung Carcinoma
- Large Cell Lung Carcinoma
- Neuroendocrine Carcinoma
- Small Cell Carcinoma
- Stage IV Non-Small Cell Lung Cancer AJCC v7

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Etoposide
- **DRUG:** Veliparib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01642251
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-28
- **Primary completion:** 2016-12-08
- **Final completion:** 2018-07-02
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01642251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01642251, "Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01642251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*